Guillaume Fond, Marc-Antoine d'Albis, Stéphane Jamain, Ryad Tamouza, Celso Arango, W Wolfgang Fleischhacker, Birte Glenthøj, Markus Leweke, Shôn Lewis, Phillip McGuire, Andreas Meyer-Lindenberg, Iris E Sommer, Inge Winter-van Rossum, Shitij Kapur, René S Kahn, Dan Rujescu, Marion Leboyer
Successful treatment of first-episode psychosis is one of the major factors that impacts long-term prognosis. Currently, there are no satisfactory biological markers (biomarkers) to predict which patients with a first-episode psychosis will respond to which treatment. In addition, a non-negligible rate of patients does not respond to any treatment or may develop side effects that affect adherence to the treatments as well as negatively impact physical health. Thus, there clearly is a pressing need for defining biomarkers that may be helpful to predict response to treatment and sensitivity to side effects in first-episode psychosis...
May 2015: Schizophrenia Bulletin